WO2001032708A1 - Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis - Google Patents
Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis Download PDFInfo
- Publication number
- WO2001032708A1 WO2001032708A1 PCT/SE1999/002009 SE9902009W WO0132708A1 WO 2001032708 A1 WO2001032708 A1 WO 2001032708A1 SE 9902009 W SE9902009 W SE 9902009W WO 0132708 A1 WO0132708 A1 WO 0132708A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wnt
- cancer
- metastasis
- cells
- synthesised peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU17007/00A AU1700700A (en) | 1999-11-05 | 1999-11-05 | Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis |
PCT/SE1999/002009 WO2001032708A1 (en) | 1999-11-05 | 1999-11-05 | Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis |
EP99960062A EP1226172A1 (en) | 1999-11-05 | 1999-11-05 | Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/SE1999/002009 WO2001032708A1 (en) | 1999-11-05 | 1999-11-05 | Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001032708A1 true WO2001032708A1 (en) | 2001-05-10 |
Family
ID=20415839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1999/002009 WO2001032708A1 (en) | 1999-11-05 | 1999-11-05 | Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1226172A1 (en) |
AU (1) | AU1700700A (en) |
WO (1) | WO2001032708A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003092719A3 (en) * | 2002-04-29 | 2004-03-18 | Yissum Res Dev Co | Methods and compositions for modulating beta-catenin phosphorylation |
WO2006130082A1 (en) * | 2005-05-30 | 2006-12-07 | Forskarpatent I Syd Ab | A peptide ligand to impair cancer cell migration |
WO2009134204A1 (en) * | 2008-04-30 | 2009-11-05 | Forskarpatent I Syd Ab | RESTORATION OF ESTROGEN RECEPTOR-α ACTIVITY |
US7682607B2 (en) | 2001-05-01 | 2010-03-23 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
US7713526B2 (en) | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
WO2013006129A1 (en) | 2011-07-01 | 2013-01-10 | Wntresearch Ab | Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients |
EP3229831B1 (en) * | 2014-12-10 | 2020-03-11 | Hyperstem SA | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023730A1 (en) * | 1996-11-27 | 1998-06-04 | The Penn State Research Foundation | Compounds and methods for treating cancer |
EP0885959A2 (en) * | 1997-05-23 | 1998-12-23 | Smithkline Beecham Plc | Human Wnt-5b protein |
WO2000021555A1 (en) * | 1998-10-15 | 2000-04-20 | President And Fellows Of Harvard College | Contraception through antagonizing wnt; oocyte maturation with wnt polypeptide |
-
1999
- 1999-11-05 EP EP99960062A patent/EP1226172A1/en not_active Withdrawn
- 1999-11-05 AU AU17007/00A patent/AU1700700A/en not_active Abandoned
- 1999-11-05 WO PCT/SE1999/002009 patent/WO2001032708A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023730A1 (en) * | 1996-11-27 | 1998-06-04 | The Penn State Research Foundation | Compounds and methods for treating cancer |
EP0885959A2 (en) * | 1997-05-23 | 1998-12-23 | Smithkline Beecham Plc | Human Wnt-5b protein |
WO2000021555A1 (en) * | 1998-10-15 | 2000-04-20 | President And Fellows Of Harvard College | Contraception through antagonizing wnt; oocyte maturation with wnt polypeptide |
Non-Patent Citations (2)
Title |
---|
CLINICAL CANCER RESEARCH, vol. 1, no. 2, February 1995 (1995-02-01), (UNITED STATES), pages 215 - 222 * |
DATABASE MEDLINE [online] LEJEUNE S. ET AL.: "Wnt5a cloning, expression and up-regulation in human primary breast cancers", XP002954905, retrieved from 09039918 accession no. Dialog Database accession no. 99034808 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7682607B2 (en) | 2001-05-01 | 2010-03-23 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
US7713526B2 (en) | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
WO2003092719A3 (en) * | 2002-04-29 | 2004-03-18 | Yissum Res Dev Co | Methods and compositions for modulating beta-catenin phosphorylation |
AU2006253056B2 (en) * | 2005-05-30 | 2012-03-01 | Wntresearch Ab | A peptide ligand to impair cancer cell migration |
JP2008542368A (en) * | 2005-05-30 | 2008-11-27 | フォースカーパテント イー エスイューデー アーベー | Peptide ligands for reducing cancer cell metastasis |
EP2384763A1 (en) * | 2005-05-30 | 2011-11-09 | Wntresearch AB | A peptide ligand to impair cancer cell migration |
WO2006130082A1 (en) * | 2005-05-30 | 2006-12-07 | Forskarpatent I Syd Ab | A peptide ligand to impair cancer cell migration |
CN101189258B (en) * | 2005-05-30 | 2012-11-21 | 温特研究公司 | A peptide ligand to impair cancer cell migration |
US8674060B2 (en) | 2005-05-30 | 2014-03-18 | Wntresearch Ab | Peptide ligand to impair cancer cell migration |
WO2009134204A1 (en) * | 2008-04-30 | 2009-11-05 | Forskarpatent I Syd Ab | RESTORATION OF ESTROGEN RECEPTOR-α ACTIVITY |
CN102056939A (en) * | 2008-04-30 | 2011-05-11 | 温特研究公司 | Restoration of estrogen receptor-alpha activity |
WO2013006129A1 (en) | 2011-07-01 | 2013-01-10 | Wntresearch Ab | Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients |
US9278119B2 (en) | 2011-07-01 | 2016-03-08 | Wntresearch Ab | Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients |
EP3229831B1 (en) * | 2014-12-10 | 2020-03-11 | Hyperstem SA | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors |
US10688167B2 (en) | 2014-12-10 | 2020-06-23 | Hyperstem Sa | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors |
US11357840B2 (en) | 2014-12-10 | 2022-06-14 | Hyperstem Sa | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors |
Also Published As
Publication number | Publication date |
---|---|
EP1226172A1 (en) | 2002-07-31 |
AU1700700A (en) | 2001-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Glycolysis links reciprocal activation of myeloid cells and endothelial cells in the retinal angiogenic niche | |
Aguirre-Ghiso et al. | Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo | |
Hou et al. | The critical role of CD133+ CD44+/high tumor cells in hematogenous metastasis of liver cancers | |
Penar et al. | Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain | |
Kang et al. | Activated STAT3 regulates hypoxia-induced angiogenesis and cell migration in human glioblastoma | |
Rubinstein et al. | The distribution of myosin heavy chain isoforms among rat extraocular muscle fiber types | |
McGary et al. | A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo | |
Fournier et al. | Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells | |
Wendt et al. | p130Cas is required for mammary tumor growth and transforming growth factor-β-mediated metastasis through regulation of Smad2/3 activity | |
US20130338028A1 (en) | Taz/wwtr1 for diagnosis and treatment of cancer | |
CN102099491A (en) | Novel targets for regulation of angiogenesis | |
Chiu et al. | Glucose-regulated protein 78 regulates multiple malignant phenotypes in head and neck cancer and may serve as a molecular target of therapeutic intervention | |
Gallo et al. | RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells | |
US8383349B2 (en) | Bone morphogenetic protein antagonist and uses thereof | |
Wong et al. | Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer | |
Xu et al. | Hypoxia stimulates invasion and migration of human cervical cancer cell lines HeLa/SiHa through the Rab11 trafficking of integrin αvβ3/FAK/PI3K pathway-mediated Rac1 activation | |
Zhang et al. | Retracted: long noncoding RNA MT1JP inhibits proliferation, invasion, and migration while promoting apoptosis of glioma cells through the activation of PTEN/Akt signaling pathway | |
Hao et al. | JAM-C promotes lymphangiogenesis and nodal metastasis in non-small cell lung cancer | |
Berns et al. | Antiproliferative effects of suramin on androgen responsive tumour cells | |
Bello et al. | IS20I, a specific αvβ3 integrin inhibitor, reduces glioma growth in vivo | |
Liu et al. | Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer | |
Rashid et al. | Identification of epitopes within integrin β4 for binding of auto-antibodies in ocular cicatricial and mucous membrane pemphigoid: preliminary report | |
CA3007877A1 (en) | Combined preparations of pkm2 modulators and hmgb1 | |
Feng et al. | PTTG1 cooperated with GLI1 leads to epithelial-mesenchymal transition in esophageal squamous cell cancer | |
Dhawan et al. | The lymphotoxin-β receptor is an upstream activator of NF-κB-mediated transcription in melanoma cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 17007 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09704779 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999960062 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999960062 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999960062 Country of ref document: EP |